PMV Pharmaceuticals, Inc. (PMVP)

NASDAQ: PMVP · IEX Real-Time Price · USD
1.610
+0.010 (0.63%)
Apr 17, 2024, 4:00 PM EDT - Market closed
0.63%
Market Cap 82.82M
Revenue (ttm) n/a
Net Income (ttm) -68.96M
Shares Out 51.44M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 275,540
Open 1.600
Previous Close 1.600
Day's Range 1.600 - 1.660
52-Week Range 1.175 - 9.720
Beta 1.64
Analysts Strong Buy
Price Target 8.00 (+396.89%)
Earnings Date May 8, 2024

About PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 63
Stock Exchange NASDAQ
Ticker Symbol PMVP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PMVP stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 396.89% from the latest price.

Price Target
$8.0
(396.89% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic th...

21 days ago - GlobeNewsWire

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

PRINCETON, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic th...

4 weeks ago - GlobeNewsWire

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic the...

6 weeks ago - GlobeNewsWire

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

PRINCETON, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic the...

3 months ago - GlobeNewsWire

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic the...

3 months ago - GlobeNewsWire

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic the...

5 months ago - GlobeNewsWire

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

PRINCETON, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic the...

6 months ago - GlobeNewsWire

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic the...

6 months ago - GlobeNewsWire

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic th...

7 months ago - GlobeNewsWire

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic the...

9 months ago - GlobeNewsWire

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic the...

11 months ago - GlobeNewsWire

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

PRINCETON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ther...

1 year ago - GlobeNewsWire

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic th...

1 year ago - GlobeNewsWire

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumo...

1 year ago - GlobeNewsWire

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor...

1 year ago - GlobeNewsWire

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

CRANBURY, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ther...

1 year ago - GlobeNewsWire

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ther...

1 year ago - GlobeNewsWire

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

CRANBURY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-...

1 year ago - GlobeNewsWire

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

CRANBURY, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor...

2 years ago - GlobeNewsWire

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

CRANBURY, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-...

2 years ago - GlobeNewsWire

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...

2 years ago - GlobeNewsWire

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

CRANBURY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic the...

2 years ago - GlobeNewsWire

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic the...

2 years ago - GlobeNewsWire

PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

CRANBURY, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) --  PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic the...

2 years ago - GlobeNewsWire